Anticancer agent containing dendritic cell having RNA virus transferred thereinto
The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination.
1. A method for producing an anticancer agent, which comprises:
introducing a Sendai virus Z strain able to replicate its genome into a CD11c+immature dendritic cell, wherein said genome of the Sendai virus undergoes replication in the dendritic cell, thereby inducing maturation of said dendritic cell, and
formulating the anticancer agent comprising the dendritic cell containing the virus and a pharmaceutical acceptable carrier or media.
2. A method for suppressing a cancer, which comprises:
introducing a Sendai virus Z strain able to replicate its genome into a CD11c+ immature dendritic cell, wherein said genome of the Sendai virus undergoes replication in the dendritic cell, thereby inducing maturation of said dendritic cell, and
administering to a subject having a cancer the dendritic cell containing the virus able to replicate its genome.
3. The method claim 1 , wherein the virus does not contain a foreign gene.
4. The method claim 2 , wherein the virus does not contain a foreign gene.
5. The method of claim 1 , wherein the virus does not form an infectious virion.
6. The method of claim 2 , wherein the virus does not form an infectious virion.
7. The method of claim 1 , wherein the virus encodes an IFN-β.
8. The method of claim 2 , wherein the virus encodes an IFN-β.
9. The method of claim 1 , wherein the virus encodes a soluble FGF receptor.
10. The method of claim 2 , wherein the virus encodes a soluble FGF receptor.
11. The method of claim 1 , wherein the virus encodes a soluble PDGF receptor α.
12. The method of claim 2 , wherein the virus encodes a soluble PDGF receptor α.
13. The method of claim 2 , wherein the virus is an infectious or non-infectious virion.
14. The method of claim 2 , wherein the virus is an infectious or non-infectious virion.
15. The method of claim 1 , wherein the virus is a genome RNA-protein complex.
16. The method of claim 2 , wherein the virus is a genome RNA-protein complex.
17. The method claim 1 , wherein said virus is SeV-GFP or an attenuated or temperature-sensitive mutant thereof, wherein said Sendai virus has further been modified not to contain a foreign gene or modified to encode a desired foreign gene.
18. The method claim 2 , wherein said virus is SeV-GFP or an attenuated or temperature-sensitive mutant thereof, wherein said Sendai virus has further been modified not to contain a foreign gene or modified to encode a desired foreign gene.